Growth Metrics

Pfizer (PFE) Current Deferred Tax Assets (2016 - 2026)

Pfizer has reported Current Deferred Tax Assets over the past 17 years, most recently at $3.6 billion for Q1 2026.

  • Quarterly Current Deferred Tax Assets rose 23.72% to $3.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.6 billion through Mar 2026, up 23.72% year-over-year, with the annual reading at $4.0 billion for FY2025, 19.7% up from the prior year.
  • Current Deferred Tax Assets was $3.6 billion for Q1 2026 at Pfizer, down from $4.0 billion in the prior quarter.
  • Over five years, Current Deferred Tax Assets peaked at $4.2 billion in Q1 2024 and troughed at $2.5 billion in Q4 2022.
  • The 5-year median for Current Deferred Tax Assets is $3.6 billion (2022), against an average of $3.5 billion.
  • Year-over-year, Current Deferred Tax Assets tumbled 34.38% in 2022 and then soared 53.97% in 2023.
  • A 5-year view of Current Deferred Tax Assets shows it stood at $3.6 billion in 2022, then grew by 11.21% to $4.0 billion in 2023, then decreased by 16.69% to $3.3 billion in 2024, then increased by 19.7% to $4.0 billion in 2025, then dropped by 9.55% to $3.6 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Current Deferred Tax Assets are $3.6 billion (Q1 2026), $4.0 billion (Q4 2025), and $3.9 billion (Q3 2025).